Navigation Links
Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Date:4/4/2011

WORCESTER, Mass. and TORONTO, April 4, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of a report comparing the clinical characteristics of three different immunotherapeutic peptide vaccines designed for immunotherapy of breast cancer.  One of those, AE37, is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).

(Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

The AE37 peptide, which is modified by proprietary technology to increase specific immunity against the HER2 protein expressed on cancer cells, is currently the subject of a randomized and controlled Phase II trial in patients with breast cancer as well as a Phase I trial in patients with prostate cancer that was recently completed.  

The report, entitled "Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines", appeared in the February issue of Expert Review of Vaccines.  The three peptides compared were AE37, E75 (also known as NeuVax™) and GP2.  Both E75 and GP2 represent unmodified peptides derived from the HER2 protein selected to stimulate cytotoxic CD8+ T cells.  

In contrast, AE37 is a modified HER2-derived peptide designed to stimulate CD4+ T helper cells (in addition to CD8+ T cells).  All peptides were shown to be safe and well tolerated by breast cancer patients.  The order of potency of specific HER2 immunity induced by the peptides was: AE37 followed by GP2 followed by E75.  Though not yet confirmed, there is evidence suggesting that a better immunological response against HER2 is associated with decreased disease recurrence and mortality.

A further study is being presented at the 102nd Annual Meeting of the American Assoc
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces $3.0 Million Capital Investment
2. Generex Provides Additional Details for October 21st Live Video Webcast
3. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
4. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
7. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
8. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. Techne Corporation Announces Acquisition
11. Life Technologies Announces Launch of 2010 Online Annual Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... NASA astronaut Scott Kelly , who is making final ... living and working on the International Space Station, will be ... EDT Monday, March 9. Kelly will participate from ... weeks of his training. The interviews will be preceded at ... mission training and previous spaceflights. To schedule an ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Experts and ... schedules for one event: the Alltech REBELation exploring innovation, ... May 17-20. Now in its 31st year, Alltech’s annual ... 70 countries, and the opportunity to join the REBELation ... 7 at 11:59 p.m. EST, at which point the ...
(Date:3/3/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new ... in North America , the Middle ... "Bidding activity in 2015 continues to be robust" said Derek ... for bidding in 2014, we are pleased to see the bidding ... organization,s renewed focus on select market segments where we can add ...
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ... Therapy Market, 2015 - 2025" report to their ... report provides an extensive study on the marketed and ... carried out in this field for over a decade ... in Asian markets; one approved in the EU). There ...
Breaking Biology Technology:NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... John Reed with Fair Political,Practices Commission, SANTA MONICA, ... C. Reed, must resign from the board for,violating conflict ... (FTCR) said today., Reed intervened and attempted to ... affiliated with the Burnham Institute, where Reed is,president and ...
... ALTO, Calif., Nov. 21 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... will be webcast live during the 19th Annual ... 2007 at 2:30 p.m. Eastern,Time. The presentation will ... and,may be accessed under the Investor Relations tab ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... officer of ViroPharma, will present,at the Lazard Capital ... on Tuesday, November 27, 2007. The conference is ... ViroPharma also announced that Michel de Rosen, president ...
Cached Biology Technology:California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says 2California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says 319th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2ViroPharma to Present at Two Upcoming Healthcare Conferences 2
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... from the Florida Everglades can withstand exposure to salt ... ocean and estuarine environments, according to research in the ... Biology and Ecology . This recent study, based ... Geological Survey, provides initial evidence that pythons ...
... CALIF (Jan 4, 2012) Daily doses of ... improved menopausal symptoms, including significantly reducing hot flash ... study in postmenopausal Japanese women published in the ... "It is believed that S-equol, produced from ...
... Therapeutic hypothermia has been proven to reduce mortality and ... was rarely used in a sample of more than ... Hypothermia and Temperature Management, a peer-reviewed journal published by ... www.liebertpub.com/ther Therapeutic hyperthermia was used in ...
Cached Biology News:Salt water alone unlikely to halt Burmese python invasion 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 3New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 4New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 5
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
FGF Receptor 1 Antibody...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: